This trial is trying to understand how safe and tolerable a new oral treatment (APL-101) is for patients with non-small cell lung cancer and other advanced cancers.
This trial is treating patients with non-small cell lung cancer or advanced cancer with Exon 14 skip mutations and MET-dysregulations.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Commercial Sponsor
Apollomics Inc.
Summary
The Phase 2 portion of this trial is now open for people with Non-Small Cell Lung Cancer and other advanced cancers with Exon 14 skip mutations and MET-dysregulations. Participants will receive will receive the recommended Phase 2 dose (RP2D) of APL-101 at 400mg daily dose (200mg twice a day).
Recruiting Hospitals Read More